Victor G. Miranda

Victor G. Miranda

Auto-generated profile, based on publicly available information

Victor G. Miranda

Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2019 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
LFLiberty François-Moutal<&sol;a>12<&sol;sup>
Liberty François-Moutal<&sol;a>12<&sol;sup>
SPSamantha Perez-Miller
Samantha Perez-Miller
DSDavid D. Scott
David D. Scott
VMVictor G. Miranda
Victor G. Miranda
NMNiloufar Mollasalehi
Niloufar Mollasalehi
MKMay Khanna
May Khanna
Transactive response DNA binding protein (TDP-43) is a key player in neurodegenerative diseases. In this review, we have gathered and presented structural information on the different regions of TDP-43 with high resolution structures available. A thorough understanding of TDP-43 structure, effect of modifications, aggregation and sites of localization is necessary as we develop therapeutic strategies targeting TDP-43 for neurodegenerative diseases. We discuss how different domains as well as post-translational modification may influence TDP-43 overall structure, aggregation and droplet formation. The primary aim of the review is to utilize structural insights as we develop an understanding of the deleterious behavior of TDP-43 and highlight locations of established and proposed post-translation modifications. TDP-43 structure and effect on localization is paralleled by many RNA-binding proteins and this review serves as an example of how structure may be modulated by numerous compounding elements.

26 June 2019 in ACS Chemical Biology
Verified
Journal Article
Closed access
LFLiberty François-Moutal
Liberty François-Moutal
RFRazaz Felemban
Razaz Felemban
DSDavid D. Scott
David D. Scott
MSMelissa R. Sayegh
Melissa R. Sayegh
VMVictor G. Miranda
Victor G. Miranda
MKMay Khanna
May Khanna

7 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
EHEdward P. Harvey
Edward P. Harvey
JSJung-Eun Shin
Jung-Eun Shin
MSMeredith A. Skiba
Meredith A. Skiba
GNGenevieve R. Nemeth
Genevieve R. Nemeth
JHJoseph D. Hurley
Joseph D. Hurley
AKAndrew C. Kruse
Andrew C. Kruse
Antibodies are essential biological research tools and important therapeutic agents, but some exhibit non-specific binding to off-target proteins and other biomolecules. Such polyreactive antibodies compromise screening pipelines, lead to incorrect and irreproducible experimental results, and are generally intractable for clinical development. Here, we design a set of experiments using a diverse naïve synthetic camelid antibody fragment (nanobody) library to enable machine learning models to accurately assess polyreactivity from protein sequence (AUC > 0.8). Moreover, our models provide quantitative scoring metrics that predict the effect of amino acid substitutions on polyreactivity. We experimentally test our models’ performance on three independent nanobody scaffolds, where over 90% of predicted substitutions successfully reduced polyreactivity. Importantly, the models allow us to diminish the polyreactivity of an angiotensin II type I receptor antagonist nanobody, without compromising its functional properties. We provide a companion web-server that offers a straightforward means of predicting polyreactivity and polyreactivity-reducing mutations for any given nanobody sequence.

1 April 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
LFLiberty François-Moutal
Liberty François-Moutal
VMVictor G. Miranda
Victor G. Miranda
NMNiloufar Mollasalehi
Niloufar Mollasalehi
VGVijay Gokhale
Vijay Gokhale
MKMay Khanna
May Khanna

10 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EHEdward P. Harvey
Edward P. Harvey
JSJeffrey S Smith
Jeffrey S Smith
JHJoseph D. Hurley
Joseph D. Hurley
AGAlyana Granados
Alyana Granados
ESErnst W. Schmid
Ernst W. Schmid
KSKatherine J. Susa
Katherine J. Susa
Antibodies are central mediators of the adaptive immune response, and they are powerful research tools and therapeutics. Antibody discovery requires substantial experimental effort, such as immunization campaigns or in vitro library screening. Predicting antibody-antigen binding a priori remains challenging. However, recent machine learning methods raise the possibility of in silico antibody discovery, bypassing or reducing initial experimental bottlenecks. Here, we report a virtual screen using AlphaFold-Multimer (AF-M) that prospectively identified nanobody binders to MRGPRX2, a G protein-coupled receptor (GPCR) and therapeutic target for the treatment of pseudoallergic inflammation and itch. Using previously reported nanobody-GPCR structures, we identified a set of AF-M outputs that effectively discriminate between interacting and non-interacting nanobody-GPCR pairs. We used these outputs to perform a prospective in silico screen, identified nanobodies that bind MRGPRX2 with high affinity, and confirmed activity in signaling and functional cellular assays. Our results provide a proof of concept for fully computational antibody discovery pipelines that can circumvent laboratory experiments.

23 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
EHEdward P. Harvey
Edward P. Harvey
JSJeffrey S Smith
Jeffrey S Smith
JHJoseph D. Hurley
Joseph D. Hurley
AGAlyana J. Granados
Alyana J. Granados
ESErnst W. Schmid
Ernst W. Schmid
KSKatherine J. Susa
Katherine J. Susa
Antibodies are central mediators of the adaptive immune response, and they are powerful research tools and therapeutics. Antibody discovery requires substantial experimental effort, such as immunization campaigns or in vitro library screening. Predicting antibody-antigen binding a priori remains challenging. However, recent machine learning methods raise the possibility of in silico antibody discovery, bypassing or reducing initial experimental bottlenecks. Here, we report a virtual screen using AlphaFold-Multimer (AF-M) that prospectively identified nanobody binders to MRGPRX2, a G protein-coupled receptor (GPCR) and therapeutic target for the treatment of pseudoallergic inflammation and itch. Using previously reported nanobody-GPCR structures, we identified a set of AF-M outputs that effectively discriminate between interacting and non-interacting nanobody-GPCR pairs. We used these outputs to perform a prospective in silico screen, identified nanobodies that bind MRGPRX2 with high affinity, and confirmed activity in signaling and functional cellular assays. Our results provide a proof of concept for fully computational antibody discovery pipelines that can circumvent laboratory experiments.